ArticleTranslational cancer research2026
MicroRNA-374b-5p suppresses osteosarcoma progression via the PDPK1-mediated AKT pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs (miRNAs) have been verified to be involved in various biological processes through regulating their target genes, and some previous studies have revealed the antitumour role of microRNA-374b-5p (miR-374b-5p) in several tumours. Therefore, the purpose of this study was to explore the functions and potential mechanisms of miR-374b-5p in osteosarcoma (OS) progression. Methods: The differentially expressed gene miR-374b-5p was discovered in the dataset GSE65071 from the Gene Expression Omnibus (GEO) database via bioinformatics analysis, and its expression levels in OS tissues and cell lines were confirmed by RNA fluorescence in situ hybridization (FISH) staining and quantitative real-time polymerase chain reaction (qRT-PCR). OS cell proliferation ability was evaluated by Cell Counting Kit-8 (CCK-8) assay and colony formation assay, cell migration and invasion abilities were assessed by Transwell assays, and apoptosis was detected by flow cytometry. The underlying mechanisms of miR-374b-5p in regulating OS progression were explored by qRT-PCR, dual-luciferase reporter assay and western blotting. Results: In this study, miR-374b-5p expression was confirmed to be significantly down-regulated in OS, and miR-374b-5p overexpression could inhibit the proliferation, migration, and invasion abilities but promote apoptosis of OS cells. Mechanism studies revealed that miR-374b-5p suppressed the AKT pathway via negatively regulating the expression of phosphoinositide-dependent protein kinase 1 (PDPK1). Notably, PDPK1 were highly expressed in OS cell lines, as verified by qRT-PCR, and PDPK1-silencing considerably restrained OS progression. Moreover, the inhibitory effects of miR-374b-5p on OS progression were partially reversed by PDPK1 overexpression both Conclusions: MiR-374b-5p was lowly expressed in OS, and its upregulation inhibited the progression of OS by directly targeting PDPK1 to affect the activity of the AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.